151 related articles for article (PubMed ID: 24510745)
1. Relevance weighting of tier 1 endocrine screening endpoints by rank order.
Borgert CJ; Stuchal LD; Mihaich EM; Becker RA; Bentley KS; Brausch JM; Coady K; Geter DR; Gordon E; Guiney PD; Hess F; Holmes CM; LeBaron MJ; Levine S; Marty S; Mukhi S; Neal BH; Ortego LS; Saltmiras DA; Snajdr S; Staveley J; Tobia A
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):90-113. PubMed ID: 24510745
[TBL] [Abstract][Full Text] [Related]
2. Hypothesis-driven weight of evidence framework for evaluating data within the US EPA's Endocrine Disruptor Screening Program.
Borgert CJ; Mihaich EM; Ortego LS; Bentley KS; Holmes CM; Levine SL; Becker RA
Regul Toxicol Pharmacol; 2011 Nov; 61(2):185-91. PubMed ID: 21803110
[TBL] [Abstract][Full Text] [Related]
3. Hypothesis-driven weight of evidence analysis to determine potential endocrine activity of MTBE.
de Peyster A; Mihaich E
Regul Toxicol Pharmacol; 2014 Aug; 69(3):348-70. PubMed ID: 24813373
[TBL] [Abstract][Full Text] [Related]
4. The use and acceptance of Other Scientifically Relevant Information (OSRI) in the U.S. Environmental Protection Agency (EPA) Endocrine Disruptor Screening Program.
Bishop PL; Willett CE
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):3-22. PubMed ID: 24151143
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.
Borgert CJ; Mihaich EM; Quill TF; Marty MS; Levine SL; Becker RA
Regul Toxicol Pharmacol; 2011 Apr; 59(3):397-411. PubMed ID: 21251942
[TBL] [Abstract][Full Text] [Related]
6. Hypothesis-driven weight-of-evidence analysis of endocrine disruption potential: a case study with triclosan.
Mihaich E; Capdevielle M; Urbach-Ross D; Slezak B
Crit Rev Toxicol; 2017 Apr; 47(4):263-285. PubMed ID: 28128023
[TBL] [Abstract][Full Text] [Related]
7. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
[TBL] [Abstract][Full Text] [Related]
8. Hypothesis-driven weight of evidence evaluation indicates styrene lacks endocrine disruption potential.
Borgert CJ
Crit Rev Toxicol; 2023 Feb; 53(2):53-68. PubMed ID: 37216681
[TBL] [Abstract][Full Text] [Related]
9. Chlorpyrifos: weight of evidence evaluation of potential interaction with the estrogen, androgen, or thyroid pathways.
Juberg DR; Gehen SC; Coady KK; LeBaron MJ; Kramer VJ; Lu H; Marty MS
Regul Toxicol Pharmacol; 2013 Aug; 66(3):249-63. PubMed ID: 23524272
[TBL] [Abstract][Full Text] [Related]
10. Introduction to "screening for endocrine activity-experiences with the US EPA's endocrine disruptor screening program and future considerations".
Marty S
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):1-2. PubMed ID: 24510782
[No Abstract] [Full Text] [Related]
11. Key lessons from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 male and female pubertal assays.
Stump DG; O'Connor JC; Lewis JM; Marty MS
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):43-62. PubMed ID: 24510766
[TBL] [Abstract][Full Text] [Related]
12. Screening chemicals for thyroid-disrupting activity: A critical comparison of mammalian and amphibian models.
Pickford DB
Crit Rev Toxicol; 2010 Nov; 40(10):845-92. PubMed ID: 20684730
[TBL] [Abstract][Full Text] [Related]
13. Multi-criteria decision analysis of test endpoints for detecting the effects of endocrine active substances in fish full life cycle tests.
Crane M; Gross M; Matthiessen P; Ankley GT; Axford S; Bjerregaard P; Brown R; Chapman P; Dorgeloh M; Galay-Burgos M; Green J; Hazlerigg C; Janssen J; Lorenzen K; Parrott J; Rufli H; Schäfers C; Seki M; Stolzenberg HC; van der Hoeven N; Vethaak D; Winfield IJ; Zok S; Wheeler J
Integr Environ Assess Manag; 2010 Jul; 6(3):378-89. PubMed ID: 20821701
[TBL] [Abstract][Full Text] [Related]
14. Assessing utility of thyroid in vitro screening assays through comparisons to observed impacts in vivo.
Eytcheson SA; Olker JH; Friedman KP; Hornung MW; Degitz SJ
Regul Toxicol Pharmacol; 2023 Oct; 144():105491. PubMed ID: 37666444
[TBL] [Abstract][Full Text] [Related]
15. Pronamide: Weight of evidence for potential estrogen, androgen or thyroid effects.
Marty MS; Papineni S; Coady KK; Rasoulpour RJ; Pottenger LH; Eisenbrandt DL
Regul Toxicol Pharmacol; 2015 Jul; 72(2):405-22. PubMed ID: 25846366
[TBL] [Abstract][Full Text] [Related]
16. Analysis of EPA's endocrine screening battery and recommendations for further review.
Schapaugh AW; McFadden LG; Zorrilla LM; Geter DR; Stuchal LD; Sunger N; Borgert CJ
Regul Toxicol Pharmacol; 2015 Aug; 72(3):552-61. PubMed ID: 26044367
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of ammonium perchlorate in the endocrine disruptor screening and testing program's male pubertal protocol: ability to detect effects on thyroid endpoints.
Stoker TE; Ferrell JM; Laws SC; Cooper RL; Buckalew A
Toxicology; 2006 Nov; 228(1):58-65. PubMed ID: 17011691
[TBL] [Abstract][Full Text] [Related]
18. Effects of altered food intake during pubertal development in male and female wistar rats.
Laws SC; Stoker TE; Ferrell JM; Hotchkiss MG; Cooper RL
Toxicol Sci; 2007 Nov; 100(1):194-202. PubMed ID: 17728285
[TBL] [Abstract][Full Text] [Related]
19. A hypothesis-driven weight-of-evidence analysis to evaluate potential endocrine activity of perfluorohexanoic acid.
Borghoff SJ; Fitch S; Rager JE; Huggett D
Regul Toxicol Pharmacol; 2018 Nov; 99():168-181. PubMed ID: 30240830
[TBL] [Abstract][Full Text] [Related]
20. Application of an integrated testing strategy to the U.S. EPA endocrine disruptor screening program.
Willett CE; Bishop PL; Sullivan KM
Toxicol Sci; 2011 Sep; 123(1):15-25. PubMed ID: 21642633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]